Company intelligence / Profile preview

Noctrix Health

Pleasanton, California, United Statesnoctrixhealth.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company's lead product, Nidra™, delivers TOMAC therapy and has been clinically validated to reduce symptoms of drug-refractory Restless Legs Syndrome and improve sleep quality. It received FDA Breakthrough Device Designation in June 2020 and De Novo authorization in April 2023. Clinical studies have demonstrated efficacy including reduction of opioid use among RLS patients. Dedicated CMS reimbursement codes were issued in early 2024.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation device therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Nidra

Commercial

Indications: Restless Legs Syndrome

Partnerships

Angelini Ventures (investor/partner)ResMed (investor/partner)Asahi Kasei Corporation (investor/partner)

Beyond the preview

Go deeper on Noctrix Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Noctrix Health.

Explore the full profile